Sign up for ICER's Weekly View Newsletter

 

Weekly View


May 21, 2026

From the desk of Priya Ranade

Good morning, everyone.

Happy Memorial Day weekend! This Weekly View is hitting your inbox a day early, so you’ll still catch this week’s drug pricing and policy news.

 

Before you log off, make sure to register for the ICER Scientific Advice (ISA) webinar, which will take place on Wednesday, May 27th at 10 AM ET. ISA is a new offering from ICER that advises companies with clinical stage assets on evidence generation strategies to support a more comprehensive assessment of clinical effectiveness and value. The webinar will feature Rachel Salzman, CEO of Armatus Bio, who will share her experiences with the ISA program. Register here.

Let's see what happened this week...

 

ICER in the News

 

Drug prices in US are too high. Here’s how to lower them.

The Boston Globe

Researchers from Harvard’s Kennedy School and Brown’s School of Public Health penned an op-ed praising the CMS drug price negotiation program while also asserting that it needs to move faster and include more treatments. They also mention the role of ICER in the US health care system:

 

“The Food and Drug Administration asks whether a drug is safe and effective. It does not ask whether a $200,000-a-year drug is worth $200,000 a year.

 

Many wealthy nations have some version of that question built into their systems, including the US. It has the Institute for Clinical and Economic Review, or ICER, an independent, privately funded agency that rigorously analyzes whether drug prices are justified by clinical benefit. Its work is credible and widely respected. It is also entirely advisory. No payer is required to consider it. Giving ICER’s analyses real weight in Medicare’s negotiating positions — not as a trigger for coverage denials, but as an anchor for what we are willing to pay — would help close the gap between what drugs cost and what they do for patients.

 

Expanding negotiation, fixing the patent system, and requiring that price reflect value at launch would not eliminate pharmaceutical innovation — they would redirect it toward the patients it is supposed to serve.”

 
Pharmaceutical News

MUST READS

The Average Marketplace Deductible Grew by About $1,000 Per Person in 2026, With More Enrollees Shifting to Higher-Deductible Plans as Enhanced Tax Credits Expired

KFF Health News

The average Affordable Care Act (ACA) Marketplace deductible experienced the steepest increase in history—growing by 37% or over $1,000, from $2,759 in 2025 to $3,786 in 2026 as enhanced premium tax credits expired, according to a new KFF analysis.


After the enhanced tax credits ended, many Marketplace shoppers shifted toward lower-premium, higher-deductible plans. Between 2025 and 2026, sign-ups for bronze plans jumped from 30% to 40% of total plan selections, growing from 7.3 million to 9.2 million people. 


Marketplace enrollment could ultimately decline by 21.5% or nearly five million people this year, falling from 22.3 million people in 2025 to about 17.5 million in 2026, according to KFF analysis of estimates from Wakely Consulting Group on premium payments as well as federal data.

Exclusive: US Health Secretary Kennedy backs away from some recent changes to CDC vaccine panel 

Reuters

In a new charter governing ACIP’s work announced on April 6, RFK Jr. broadened the membership requirements for potential panelists, adding expertise in toxicology, data science, and health economics, among other areas.


Kennedy’s allies praised the charter, while his critics said it could open the door for the secretary to simply reappoint some of the same advisory committee members a federal judge had blocked. Kennedy’s Health and Human Services Department on Monday withdrew the charter, without releasing a new version.

Maryland state affordability board places a price cap on Ozempic

STAT

The Maryland Prescription Drug Affordability Board agreed to set an upper payment limit for the Ozempic diabetes treatment, marking the second time that the state panel has taken such a step in recent weeks.


The board, which is designed to function like a state utility commission, will now oversee a process to lower the cost of the type 2 diabetes medicine for the state and local governments by January 2027. At the time, the price will be capped at $274 for a 30-day supply, a move the board estimates will save $5.8 million a year.

TrumpRx adds over 600 generic drugs; Mark Cuban joins White House rollout

The Hill

President Trump on Monday announced the addition of more than 600 generic drugs to his drug coupon platform TrumpRx, with billionaire investor Mark Cuban joining President Trump to endorse the website.

Docs remain skeptical of insurers' pledge to ease prior auth: AMA survey

Fierce Healthcare

As payers tout progress made under a pledge to ease burdens around prior authorizations, physicians remain skeptical, a new survey shows. The American Medical Association released the results from a poll conducted in December 2025 of 1,000 physicians on their experiences with prior authorization. Only a third (33%) of those surveyed said they believe that the payers' pledge last summer would lead to significant change.


ICER’s work on fair access for prescription drugs has established ethical criteria that payers should follow when designing coverage policies, which includes recommendations on timing for prior authorization protocols.

OTHER HEADLINES

 

Join ICER!

 

Want to work for a fast-paced, mission-driven organization? Look no further! ICER is looking to expand our team:



 

Key Upcoming Dates

 
  • 6/8: Narcolepsy -- Final Evidence Report
  • 6/11: Covid-19 -- Evidence Report

Learn more about ICER’s ongoing and recently completed reports:

Email info@icer.org for more information.

When you make a gift to ICER, you help keep ICER independent.  

 
 
 
 
 
LinkedIn Share This Email